New research findings may lead to better treatment plans for HIV patients coinfected with hepatitis C

July 24, 2014 by Sathya Achia Abraham

Using a combination antiretroviral therapy to treat HIV patients coinfected with the hepatitis C virus (HCV) not only effectively treats HIV, but also results in reduced HCV replication, according to a multi-center study published this week in Science Translational Medicine.

The findings advance what is known about the biological effects of patients coinfected with HCV and HIV and may ultimately help physicians improve treatment plans for HIV patients coinfected with hepatitis C. In the United States, coinfection affects approximately 200,000 to 300,000 people; worldwide estimates are between 4 to 8 million people.

Coinfection of HIV/HCV is associated with a higher rate of HCV replication and increased liver injury. Previously, there were concerns in treating coinfected patients with HIV antiretroviral therapy due to possible liver injury.

The study was led by researchers at the University of Cincinnati College of Medicine in collaboration with several other medical institutions, including Virginia Commonwealth University.

In the study, researchers closely examined 17 patients coinfected with HIV and hepatitis C who received already approved HIV antiretroviral drug therapies. In order to detect minor changes in the virus and immune response, patients underwent frequent evaluation and provided blood samples during a two-year span.

During the first 16 weeks, the team observed an initial increase in a marker of liver injury known as serum ALT, hepatitis C or both. However, according to lead author Kenneth Sherman, M.D., Ph.D., Gould Professor of Medicine and director of the University of Cincinnati Division of Digestive Diseases in the College of Medicine, during a period of 18 months, researchers found that viral loads for HCV returned to what was expected in a monoinfected patient suffering from HCV without HIV. Initial liver injury actually resulted from effective HIV treatment and not from toxicity.

In a statement released by the University of Cincinnati, Sherman said, "Initial response to HIV treatment results in a transient increase in HCV viral replication and evidence of . However, over time HIV suppression leads to reduced HCV replication."

"Because we used to think that increases in liver enzymes and HCV were harmful to coinfected patients starting HIV treatment, many providers caring for those with HIV got nervous which led to early discontinuation of lifesaving HIV treatment," said the principal investigator for the VCU portion of the study, Richard Sterling, M.D., professor of medicine, chief of hepatology and medical director of HIV-liver disease at VCU.

"This carefully done study tells us that these transient changes are not harmful and provide reassuring data to both patients and providers," Sterling said.

According to Sterling, future studies are needed to help tease out the mechanisms of why liver enzymes and HCV increase during this early period of starting HIV therapy.

"The data from this study tells us that treating the HIV first is safe in those coinfected. This is important as newer treatments for HCV are soon available that are not only much better tolerated, but also require a much shorter course of therapy, with higher response rates exceeding 90 percent and similar to those without HIV," he said.

The study was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences. Portions of this work were performed under the auspices of the U.S. Department of Energy.

The paper is titled: "Modulation of HCV replication after in HCV/HIV coinfected patients."

Explore further: HIV-HCV coinfection speeds HCV-related liver fibrosis

More information: "Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients." Kenneth E. Sherman, et al. Sci Transl Med 23 July 2014:
Vol. 6, Issue 246, p. 246ra98. DOI: 10.1126/scitranslmed.3008195

Related Stories

HIV-HCV coinfection speeds HCV-related liver fibrosis

February 27, 2013
(HealthDay)—Individuals who are coinfected with HIV and hepatitis C virus (HCV) exhibit liver fibrosis similar to that of individuals without HIV who are nearly 10 years older, according to research published online Feb. ...

Hepatic decompensation higher with HIV, HCV co-infection

March 18, 2014
(HealthDay)—Patients co-infected with HIV and hepatitis C virus (HCV) have higher rates of hepatic decompensation than those with HCV monoinfection, according to a study published in the March 18 issue of the Annals of ...

Transmission of hepatitis C virus following antiviral treatment

July 8, 2014
Millions of people throughout the world are infected with hepatitis C virus (HCV). Left untreated, infection results in serious complications such as cirrhosis of the liver and cancer. Many HCV-infected patients respond well ...

Predicting the outcome of hepatitis C virus treatment

July 1, 2014
Millions of people throughout the world are infected with hepatitis C virus (HCV), which can lead to cirrhosis of the liver and cancer. Directly acting antiviral agents inhibit viral proteins and have been used to successfully ...

Hepatitis C reactivation doesn't worsen survival for HIV+ patients diagnosed with lymphoma

May 30, 2014
More than a quarter of HIV+ patients are also infected with the Hepatitis C virus (HCV), which may complicate treatment and care decisions after a cancer diagnosis. The specifics of those complications haven't been well-researched ...

African American women with HIV/HCV less likely to die from liver disease

November 1, 2012
A new study shows that African American women coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are less likely to die from liver disease than Caucasian or Hispanic women. Findings in the November ...

Recommended for you

Novel therapies for multidrug-resistant bacteria

October 23, 2017
During this innovative study published in PLOS One, researchers found that novel classes of compounds, such as metal-complexes, can be used as alternatives to or to supplement traditional antibiotics, which have become ineffective ...

Key discoveries offer significant hope of reversing antibiotic resistance

October 23, 2017
Resistance to antibiotics is becoming increasingly prevalent and threatens to undermine healthcare systems across the globe. Antibiotics including penicillins, cephalosporins and carbapenems are known as β-lactams and are ...

Pneumonia vaccine under development provides 'most comprehensive coverage' to date, alleviates antimicrobial concerns

October 20, 2017
In 2004, pneumonia killed more than 2 million children worldwide, according to the World Health Organization. By 2015, the number was less than 1 million.

Newly discovered viral marker could help predict flu severity in infected patients

October 20, 2017
Flu viruses contain defective genetic material that may activate the immune system in infected patients, and new research published in PLOS Pathogens suggests that lower levels of these molecules could increase flu severity.

Migraines may be the brain's way of dealing with oxidative stress

October 19, 2017
A new perspective article highlights a compelling theory about migraine attacks: that they are an integrated mechanism by which the brain protects and repairs itself. Recent insightful findings and potential ways to use them ...

H7N9 influenza is both lethal and transmissible in animal model for flu

October 19, 2017
In 2013, an influenza virus that had never before been detected began circulating among poultry in China. It caused several waves of human infection and in late 2016, the number of people to become sick from the H7N9 virus ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.